Upamostat hydrogen (sulfate)

Upamostat (WX-671) hydrogen sulfate, a prodrug of WX-UK1 (HY-100415), is an orally active serine protease inhibitor. Upamostat hydrogen sulfate inhibits the urokinase-type plasminogen activator (uPA) system, blocking the plasminogen activation process mediated by it, thereby suppressing the invasion, migration and metastasis of tumor cells. Upamostat hydrogen sulfate can be used in the research of metastatic breast cancer and locally advanced pancreatic cancer[1].

Product Specifications

CAS Number

[798560-68-6]

Product Name Alternative

WX-671 hydrogen (sulfate)

UNSPSC

12352005

Target

PAI-1; Ser/Thr Protease

Related Pathways

Metabolic Enzyme/Protease

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Smiles

O=C(N1CCN(C([C@@H](NS(=O)(C2=C(C(C)C)C=C(C(C)C)C=C2C(C)C)=O)CC3=CC=CC(C(NO)=N)=C3)=O)CC1)OCC.O=C(N4CCN(C([C@@H](NS(=O)(C5=C(C(C)C)C=C(C(C)C)C=C5C(C)C)=O)CC6=CC=CC(C(NO)=N)=C6)=O)CC4)OCC.O=S(O)(O)=O